This past May, Pharmaceutical Executive reported that CVS Health decided to return Eli Lilly’s Zepbound to its list of ...

Pharmaceutical Executive spoke with Dr. Richard Graham, chairman and co-founder of TruTechnologies about FDA’s new program ...

This past May, Pharmaceutical Executive reported that CVS Health decided to return Eli Lilly’s Zepbound to its list of ...

Otsuka Pharmaceutical Development & Commercialization, Inc. and Otsuka Pharmaceutical Co., Ltd. (Otsuka) announced that FDA granted approval of Simtriyo (centanafadine), a once-daily extended-release ...

Specialty pharma launches depend heavily on data from outside the organization. Distributors, third-party logistics providers ...

Since then, that mindset has continued to grow at AbbVie.

FDA approval used the 505(b)(2) pathway and Phase III Luminous results to support efficacy, safety characterization, and adhesive performance in women with BMI <30 kg/m². Contraceptive efficacy in the ...

Within your prior big pharma employers, AI is now a core competitive capability as it has shortened target identification and optimized molecule design. As building world-class AI drug-discovery ...

Argenx has agreed to acquire Forte Biosciences for approximately $2.2 billion, adding a first-in-class anti-CD122 antibody with clinical proof-of-concept in vitiligo and celiac disease.

Project Trialblazer prioritizes reducing IND review timelines, but its impact on sponsor behavior may be limited when ...

Please check back later for more content.